QuidelOrtho (NASDAQ:QDEL) Updates FY 2026 Earnings Guidance

QuidelOrtho (NASDAQ:QDEL) issued an update on its FY 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 0.650-0.900 for the period, compared to the consensus earnings per share estimate of 1.850. The company issued revenue guidance of $2.5 billion-$2.6 billion, compared to the consensus revenue estimate of $2.7 billion.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on QDEL. JPMorgan Chase & Co. increased their target price on shares of QuidelOrtho from $11.00 to $12.00 and gave the company an “underweight” rating in a research report on Wednesday, July 1st. UBS Group restated a “neutral” rating and set a $12.00 target price on shares of QuidelOrtho in a research report on Thursday, May 7th. Wall Street Zen upgraded QuidelOrtho from a “sell” rating to a “hold” rating in a report on Sunday, June 28th. Zacks Research upgraded shares of QuidelOrtho from a “strong sell” rating to a “hold” rating in a research report on Monday, June 15th. Finally, Jefferies Financial Group restated a “hold” rating on shares of QuidelOrtho in a research note on Monday, June 29th. Four research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Reduce” and a consensus target price of $13.62.

QuidelOrtho Stock Down 6.7%

QDEL traded down $1.18 during trading on Thursday, hitting $16.32. 2,696,272 shares of the company’s stock were exchanged, compared to its average volume of 1,755,895. The company has a quick ratio of 0.80, a current ratio of 1.43 and a debt-to-equity ratio of 1.33. The business’s 50 day moving average is $15.70 and its two-hundred day moving average is $17.70. QuidelOrtho has a fifty-two week low of $9.92 and a fifty-two week high of $35.58. The stock has a market cap of $1.11 billion, a P/E ratio of -0.92 and a beta of 0.68.

QuidelOrtho (NASDAQ:QDEL) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.18. The firm had revenue of $630.90 million during the quarter, compared to analysts’ expectations of $618.72 million. QuidelOrtho had a negative net margin of 45.57% and a positive return on equity of 4.25%. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. As a group, equities analysts expect that QuidelOrtho will post 1.87 earnings per share for the current fiscal year.

Institutional Trading of QuidelOrtho

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in QDEL. Corient Private Wealth LLC bought a new position in shares of QuidelOrtho in the fourth quarter valued at approximately $280,000. T. Rowe Price Investment Management Inc. grew its holdings in QuidelOrtho by 7.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 11,832,098 shares of the company’s stock worth $337,925,000 after buying an additional 819,908 shares in the last quarter. Invesco Ltd. raised its position in QuidelOrtho by 19.4% in the 4th quarter. Invesco Ltd. now owns 3,470,656 shares of the company’s stock valued at $99,122,000 after buying an additional 563,893 shares during the last quarter. Moore Capital Management LP bought a new position in QuidelOrtho during the 4th quarter valued at $1,260,000. Finally, Balyasny Asset Management L.P. bought a new position in QuidelOrtho during the 4th quarter valued at $9,953,000. 99.00% of the stock is owned by institutional investors.

About QuidelOrtho

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.